Has novelty in the depression pipeline hit a wall?
This article was originally published in Scrip
Executive Summary
The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.